What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections?

How can we prevent the spread of MRSA in the hospital?

Is there a role for OPAT in the management of patients with MRSA infections?

Can we determine the appropriate duration of therapy for MRSA infections?

What stewardship tactics can be applied to the management of MRSA infections?

Can we differentiate among newer agents for MRSA bacteremia and endocarditis?

How should clinicians manage MRSA bacteremia and infective endocarditis?

How can primary care physicians manage community-associated MRSA pneumonia?

What is the optimal treatment for MRSA nosocomial pneumonia?

What are the therapeutic options for a complicated skin or skin structure MRSA infection?

How can clinicians optimally manage community-associated MRSA skin infections?

What strategies can be used to effectively manage patients with skin and soft tissue MRSA infections?

When should an alternative agent to vancomycin be considered for MRSA infections?

What are the toxicity concerns associated with using vancomycin for MRSA infections?

Should therapeutic drug monitoring be considered when using vancomycin for MRSA infections?

What is the appropriate vancomycin dosing to maximize its effectiveness?

What is vancomycin 'MIC creep'?

What is community-associated MRSA? How is it different from healthcare-acquired MRSA?

Why is the prevalence of MRSA increasing in the hospital setting?

Why is MRSA such a problematic pathogen?